Moderna to Collaborate with Karolinska Institutet and Karolinska University Hospital on Discovery of New Messenger RNA Therapeutics

Strategic research and clinical partnership will advance state-of-the-art discoveries on the use of messenger RNA (mRNA) Therapeutics™ to treat serious diseases.

Company to establish Moderna Therapeutics Sweden in Stockholm as first expansion outside the U.S.

CAMBRIDGE, Mass. and STOCKHOLM, Sweden, October 16, 2014—Moderna Therapeutics today announced a strategic, long-term collaboration with Karolinska Institutet (KI) and Karolinska University Hospital (KUH) for the discovery and development of innovative drugs using Moderna's messenger RNA (mRNA) Therapeutics™ technology. mRNA Therapeutics™ enable the in vivo production of both intracellular proteins and secreted proteins. As a result, Moderna's platform has the potential to speed the development and manufacture of treatments for many diseases that are currently untreatable with existing pharmaceutical approaches.

"This project is an important step in advancing medical science," said Professor Hans-Gustaf Ljunggren, Dean of Research at Karolinska Institutet. "It will help achieve our common goal of rapidly advancing new drug candidates into the clinic."

Under the terms of the partnership, Moderna will sponsor research grants for scientists at both institutions to conduct preclinical research with novel mRNA Therapeutics™. As this pre-clinical work is successfully completed, Moderna will conduct clinical trials of new drug candidates at Karolinska University Hospital.

"As a leading medical center, we continually strive to improve the treatment of serious diseases," said Professor Mats Eriksson, Karolinska University Hospital. "Our clinical researchers are excited to work with Moderna's groundbreaking mRNA Therapeutics platform and speed the advancement of new treatments to patients."

To solidify the scientific and clinical collaboration between the organizations, and to optimize the output of this important partnership, Moderna is creating a new laboratory in Stockholm, Sweden, located in the Novum building next to the Karolinksa University Hospital Huddinge campus.

"Moderna is investing heavily to bring mRNA Therapeutics to patients, and our science is accelerating rapidly," said Stéphane Bancel, President and founding CEO of Moderna. "This partnership puts our mRNA Therapeutics platform in the hands of Karolinska's world-class scientists and clinical researchers to develop new drugs and therapeutic approaches that cannot be done with small molecules or biologics – bringing new hope to patients with serious diseases."

"Strategically, we view this, our first academic partnership, as highly complementary to our existing drug discovery and development efforts, both with our pharmaceutical partners AstraZeneca and Alexion and with Moderna ventures such asOnkaido," added Bancel. "Given the broad potential of this revolutionary drug technology, it was critical to us to work closely with a leading academic medical institution. We are honored to be partnering with one of the best academic medical research institutions in the world."

For more information on Karolinska Institutet and Karolinska University Hospital, please visit ki.se and karolinska.se.

For more information on Moderna Therapeutics please visit modernatx.com.


About Karolinska Institutet

Karolinska Institutet is one of the world's leading medical universities. Its mission is to contribute to the improvement of human health through research and education. Karolinska Institutet accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country's broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.

About Karolinska University Hospital

Karolinska University Hospital is one of Europe's largest university hospitals and together with Karolinska Institutet has a leading role within the field of medical breakthroughs. The hospital aims to always put the patient first by providing the best possible medical expertise, treatment and care. Through innovation and active collaboration with industry and academia, it is committed to being internationally prominent in medicine, research and education.

About Moderna Therapeutics

Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate, including more than 320 patent applications covering novel nucleotide chemistries and drug compositions. The company plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as new formed ventures, like Onkaido LLC, its oncology Drug Development Company. Founded by Flagship VentureLabs, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca and Alexion Pharmaceuticalswww.modernatx.com.


For information contact:

Maria Favorito
Feinstein Kean Healthcare
617-761-6720

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.